Henovcom Bioscience

Focus: Henovcom Bioscience is a China-based biotechnology company founded in 2013 focused on small molecules, mRNA, and 505(b)(2) therapies in gene therapy. The company operates as a pre-revenue biotech with early-stage pipeline development.

Gene Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Henovcom Bioscience

AI assessmentNot Hiring

No open roles listed right now. Follow Henovcom Bioscience to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

HNC364

Parkinson's Disease

Phase 1

Clinical Trials (1)

NCT05523570A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension

Phase 1

Help build intelligence for Henovcom Bioscience

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage platform with exposure to multiple modalities (small molecules, mRNA) spanning diverse indications from Parkinson's to IPF
Opportunity to contribute to foundational science at Phase 1 stage with potential upside if any programs advance
Gene therapy focus positions the company in a high-growth, well-funded therapeutic area

Watch Out For

Zero active job openings and no hiring activity signal minimal near-term expansion or organizational momentum
All 6 pipeline programs remain in Phase 1 with no Phase 2+ programs, indicating very early clinical maturity and extended timeline to meaningful value inflection
No disclosed funding, revenue, or financial data makes it impossible to assess cash runway, stability, or competitive compensation potential

Generated by Claude from Henovcom Bioscience's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

HNC042 for Injection

Influenza

Phase 1

Clinical Trials (1)

NCT04603989A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

Phase 1

HNC042 single dose

Healthy

Phase 1

Clinical Trials (1)

NCT03740555A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Phase 1